Diagnosis, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: A review

JAMA - Journal of the American Medical Association

Volumn 315, Issue 16, 2016, Pages 1767-1777

  Sanchez, Edgar ^a   Vannier, Edouard ^a   Wormser, Gary P ^b   Hu, Linden T ^c  

^a TUFTS MEDICAL CENTER   (United States)

^b NEW YORK MEDICAL COLLEGE   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ATOVAQUONE; ATOVAQUONE PLUS AZITHROMYCIN; AZITHROMYCIN; BETA LACTAM DERIVATIVE; CEFTRIAXONE; CEFUROXIME AXETIL; CLINDAMYCIN; CLINDAMYCIN PLUS QUININE; DOXYCYCLINE; QUININE; RIFAMPICIN; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; CEFUROXIME;

BLOOD EXAMINATION; BLOOD SMEAR; CLINICAL FEATURE; DISEASE SEVERITY; DRUG EFFICACY; DRUG WITHDRAWAL; ENZYME IMMUNOASSAY; ERYTHEMA CHRONICUM MIGRANS; EVIDENCE BASED MEDICINE; FOOD AND DRUG ADMINISTRATION; HUMAN; HUMAN GRANULOCYTIC ANAPLASMOSIS; IMMUNOCOMPROMISED PATIENT; LYME DISEASE; MICROSCOPY; NONHUMAN; PARASITE IDENTIFICATION; PIROPLASMOSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW; SEROLOGY; SYSTEMATIC REVIEW; TICK BORNE DISEASE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANAPLASMA; ANAPLASMOSIS; ANIMAL; BABESIOSIS; DRUG ADMINISTRATION; ISOLATION AND PURIFICATION; MICROBIOLOGY; NEUTROPHIL;

AMOXICILLIN; ANAPLASMA; ANAPLASMOSIS; ANIMALS; ANTI-BACTERIAL AGENTS; BABESIOSIS; BLOTTING, WESTERN; CEFUROXIME; CLINDAMYCIN; DOXYCYCLINE; DRUG ADMINISTRATION SCHEDULE; HUMANS; IMMUNOENZYME TECHNIQUES; LYME DISEASE; MICROSCOPY; NEUTROPHILS; POLYMERASE CHAIN REACTION; QUININE;

EID: 84964961124     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2016.2884     Document Type: Review

References (136)

1. Tibbles CD, Edlow JA. Does this patient have erythemamigrans? JAMA. 2007;297(23):2617-2627.
2. Centers for Disease Control and Prevention (CDC). Notifiable diseases and mortality tables. MMWR Morb Mortal Wkly Rep. 2016;64: ND-923-ND-940. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6452md.htm?s-cid =mm6452md-w. Accessed April 4, 2016.
3. Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2006;43(9):1089-1134.
4. Goff DC Jr, Lloyd-Jones DM, Bennett G, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J AmColl Cardiol. 2014;63(25, pt B):2935-2959.
5. Steere AC. Lyme disease. N Engl J Med. 2001;345(2):115-125.
6. Steere AC, Sikand VK, Meurice F, et al; Lyme Disease Vaccine Study Group. Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. N Engl J Med. 1998;339(4):209-215.
7. Wormser JP, McKenna D, Nadelman RB, Nowakowski J, Weinstein A. Lyme disease in children. N Engl J Med. 1997;336(15):1107.
8. Halperin JJ. Nervous system Lyme disease. Infect Dis Clin North Am. 2015;29(2):241-253.
9. Forrester JD, Meiman J, Mullins J, et al; Centers for Disease Control and Prevention (CDC). Notes from the field: update on Lyme carditis, groups at high risk, and frequency of associated sudden cardiac death-United States. MMWR Morb Mortal Wkly Rep. 2014;63(43):982-983.
10. Arvikar SL, Steere AC. Diagnosis and treatment of Lyme arthritis. Infect Dis Clin North Am. 2015;29(2):269-280.
11. Wormser GP, Nowakowski J, Nadelman RB, Visintainer P, Levin A, Aguero-Rosenfeld ME. Impact of clinical variables on Borrelia burgdorferi-specific antibody seropositivity in acute-phase sera from patients in North America with culture-confirmed early Lyme disease. Clin Vaccine Immunol. 2008;15(10):1519-1522.
12. Herman-Giddens ME. Southern tick-associated rash illness: further considerations. Clin Infect Dis. 2012;54(6):887-888.
13. Blanton L, Keith B, Brzezinski W. Southern tick-associated rash illness: erythema migrans is not always Lyme disease. South Med J. 2008;101(7):759-760.
14. Feder HM Jr, Hoss DM, Zemel L, Telford SR III, Dias F, Wormser GP. Southern tick-associated rash illness (STARI) in the North: STARI following a tick bite in Long Island, New York. Clin Infect Dis. 2011;53(10):e142-e146.
15. Kirkland KB, Klimko TB, Meriwether RA, et al. Erythema migrans-like rash illness at a camp in North Carolina: a new tick-borne disease? Arch Intern Med. 1997;157(22):2635-2641.
16. Wormser GP, Masters E, Liveris D, et al. Microbiologic evaluation of patients fromMissouri with erythema migrans. Clin Infect Dis. 2005;40(3):423-428.
17. Niziè T, Velikanje E, Ružić-Sabljić E, Arnež M. Solitary erythema migrans in children: comparison of treatment with clarithromycin and amoxicillin. Wien KlinWochenschr. 2012;124(13-14):427-433.
18. Stupica D, Lusa L, Ruzić-Sabljić E, Cerar T, Strle F. Treatment of erythema migrans with doxycycline for 10 days versus 15 days. Clin Infect Dis. 2012;55(3):343-350.
19. Aucott J, Morrison C, Munoz B, Rowe PC, Schwarzwalder A, West SK. Diagnostic challenges of early Lyme disease: lessons from a community case series. BMC Infect Dis. 2009;9:79.
20. Massarotti EM, Luger SW, Rahn DW, et al. Treatment of early Lyme disease. Am J Med. 1992;92(4):396-403.
21. Dattwyler RJ, Volkman DJ, Conaty SM, Platkin SP, Luft BJ. Amoxycillin plus probenecid versus doxycycline for treatment of erythema migrans borreliosis. Lancet. 1990;336(8728):1404-1406.
22. Johnson BJB. Laboratory diagnostic testing for Borrelia burgdorferi infection. In: Halperin JJ, ed. Lyme Disease: An Evidence-based Approach. Cambridge, MA: CABI; 2011:73-88.
23. Nocton JJ, Dressler F, Rutledge BJ, Rys PN, Persing DH, Steere AC. Detection of Borrelia burgdorferi DNA by polymerase chain reaction in synovial fluid from patients with Lyme arthritis. N Engl J Med. 1994;330(4):229-234.
24. Chapman AS, Bakken JS, Folk SM, et al; Tickborne Rickettsial DiseasesWorking Group; CDC. Diagnosis and management of tickborne rickettsial diseases: Rocky Mountain spotted fever, ehrlichioses, and anaplasmosis-United States: a practical guide for physicians and other health-care and public health professionals. MMWR Recomm Rep. 2006;55(RR-4):1-27.
25. Aguero-Rosenfeld ME. Diagnosis of human granulocytic ehrlichiosis: state of the art. Vector Borne Zoonotic Dis. 2002;2(4):233-239.
26. Vannier E, Krause PJ. Human babesiosis. N Engl J Med. 2012;366(25):2397-2407.
27. Schriefer ME. Lyme disease diagnosis: serology. Clin Lab Med. 2015;35(4):797-814.
28. Seriburi V, Ndukwe N, Chang Z, Cox ME, Wormser GP. High frequency of false positive IgM immunoblots for Borrelia burgdorferi in clinical practice. Clin Microbiol Infect. 2012;18(12):1236-1240.
29. Fallon BA, Pavlicova M, Coffino SW, Brenner C. A comparison of Lyme disease serologic test results from 4 laboratories in patients with persistent symptoms after antibiotic treatment. Clin Infect Dis. 2014;59(12):1705-1710.
30. Aguero-Rosenfeld ME. Lyme disease: laboratory issues. Infect Dis Clin North Am. 2008;22(2):301-313.
31. Branda JA, Aguero-Rosenfeld ME, Ferraro MJ, Johnson BJ, Wormser GP, Steere AC. 2-tiered antibody testing for early and late Lyme disease using only an immunoglobulin G blot with the addition of a VlsE band as the second-tier test. Clin Infect Dis. 2010;50(1):20-26.
32. Bacon RM, Biggerstaff BJ, Schriefer ME, et al. Serodiagnosis of Lyme disease by kinetic enzyme-linked immunosorbent assay using recombinant VlsE1 or peptide antigens of Borrelia burgdorferi compared with 2-tiered testing using whole-cell lysates. J Infect Dis. 2003;187(8):1187-1199.
33. Wormser GP, Schriefer M, Aguero-Rosenfeld ME, et al. Single-tier testing with the C6 peptide ELISA kit compared with two-tier testing for Lyme disease. Diagn Microbiol Infect Dis. 2013;75(1):9-15.
34. Steere AC, McHugh G, Damle N, Sikand VK. Prospective study of serologic tests for Lyme disease. Clin Infect Dis. 2008;47(2):188-195.
35. Branda JA, Strle F, Strle K, Sikand N, Ferraro MJ, Steere AC. Performance of United States serologic assays in the diagnosis of Lyme borreliosis acquired in Europe. Clin Infect Dis. 2013;57(3):333-340.
36. Wormser GP, Tang AT, Schimmoeller NR, et al. Utility of serodiagnostics designed for use in the United States for detection of Lyme borreliosis acquired in Europe and vice versa. Med Microbiol Immunol. 2014;203(1):65-71.
37. Mathiesen MJ, Christiansen M, Hansen K, Holm A, Asbrink E, Theisen M. Peptide-based OspC enzyme-linked immunosorbent assay for serodiagnosis of Lyme borreliosis. J Clin Microbiol. 1998;36(12):3474-3479.
38. Branda JA, Linskey K, Kim YA, Steere AC, Ferraro MJ. Two-tiered antibody testing for Lyme disease with use of 2 enzyme immunoassays, a whole-cell sonicate enzyme immunoassay followed by a VlsE C6 peptide enzyme immunoassay. Clin Infect Dis. 2011;53(6):541-547.
39. Porwancher RB, Hagerty CG, Fan J, et al. Multiplex immunoassay for Lyme disease using VlsE1-IgG and pepC10-IgMantibodies: improving test performance through bioinformatics. Clin Vaccine Immunol. 2011;18(5):851-859.
40. Wormser GP, Levin A, Soman S, Adenikinju O, Longo MV, Branda JA. Comparative cost-effectiveness of two-tiered testing strategies for serodiagnosis of Lyme disease with noncutaneous manifestations. J Clin Microbiol. 2013;51(12):4045-4049.
41. Lipsett SC, Pollock NR, Branda JA, et al. The positive predictive value of Lyme ELISA for the diagnosis of Lyme disease in children. Pediatr Infect Dis J. 2015;34(11):1260-1262.
42. Shapiro ED. Clinical practice: Lyme disease. N Engl J Med. 2014;370(18):1724-1731.
43. Lantos PM, Branda JA, Boggan JC, et al. Poor positive predictive value of Lyme disease serologic testing in an area of low disease incidence. Clin Infect Dis. 2015;61(9):1374-1380.
44. Avery RA, Frank G, Eppes SC. Diagnostic utility of Borrelia burgdorferi cerebrospinal fluid polymerase chain reaction in children with Lyme meningitis. Pediatr Infect Dis J. 2005;24(8):705-708.
45. Steere AC, Berardi VP, Weeks KE, Logigian EL, Ackermann R. Evaluation of the intrathecal antibody response to Borrelia burgdorferi as a diagnostic test for Lyme neuroborreliosis. J Infect Dis. 1990;161(6):1203-1209.
46. Hytönen J, Kortela E, Waris M, Puustinen J, Salo J, Oksi J. CXCL13 and neopterin concentrations in cerebrospinal fluid of patients with Lyme neuroborreliosis and other diseases that cause neuroinflammation. J Neuroinflammation. 2014;11:103.
47. Sillanpää H, Skogman BH, Sarvas H, Seppälä IJ, Lahdenne P. Cerebrospinal fluid chemokine CXCL13 in the diagnosis of neuroborreliosis in children. Scand J Infect Dis. 2013;45(7):526-530.
48. Tjernberg I, Henningsson AJ, Eliasson I, Forsberg P, Ernerudh J. Diagnostic performance of cerebrospinal fluid chemokine CXCL13 and antibodies to the C6-peptide in Lyme neuroborreliosis. J Infect. 2011;62(2):149-158.
49. Ljostad U, Mygland A. CSF B-lymphocyte chemoattractant (CXCL13) in the early diagnosis of acute Lyme neuroborreliosis. J Neurol. 2008;255(5):732-737.
50. Sapi E, Pabbati N, Datar A, Davies EM, Rattelle A, Kuo BA. Improved culture conditions for the growth and detection of Borrelia from human serum. Int J Med Sci. 2013;10(4):362-376.
51. Johnson BJ, Pilgard MA, Russell TM. Assessment of new culture method for detection of Borrelia species from serum of Lyme disease patients. J Clin Microbiol. 2014;52(3):721-724.
52. Stricker RB, Winger EE. Natural killer cells in chronic Lyme disease. Clin Vaccine Immunol. 2009;16(11):1704.
53. Marques A, Brown MR, Fleisher TA. Natural killer cell counts are not different between patients with post-Lyme disease syndrome and controls. Clin Vaccine Immunol. 2009;16(8):1249-1250.
54. Halperin JJ. Nervous system Lyme disease. Clin Lab Med. 2015;35(4):779-795.
55. Barclay SS, Melia MT, Auwaerter PG. Misdiagnosis of late-onset Lyme arthritis by inappropriate use of Borrelia burgdorferi immunoblot testing with synovial fluid. Clin Vaccine Immunol. 2012;19(11):1806-1809.
56. Jin C, Roen DR, Lehmann PV, Kellermann GH. An enhanced ELISPOT assay for sensitive detection of antigen-specific T cell responses to Borrelia burgdorferi. Cells. 2013;2(3):607-620.
57. Klempner MS, Schmid CH, Hu L, et al. Intralaboratory reliability of serologic and urine testing for Lyme disease. Am J Med. 2001;110(3):217-219.
58. Wormser GP, Aguero-Rosenfeld ME, Cox ME, et al. Differences and similarities between culture-confirmed human granulocytic anaplasmosis and early Lyme disease. J Clin Microbiol. 2013;51(3):954-958.
59. Weil AA, Baron EL, Brown CM, Drapkin MS. Clinical findings and diagnosis in human granulocytic anaplasmosis: a case series from Massachusetts. Mayo Clin Proc. 2012;87(3):233-239.
60. Bakken JS, Aguero-Rosenfeld ME, Tilden RL, et al. Serial measurements of hematologic counts during the active phase of human granulocytic ehrlichiosis. Clin Infect Dis. 2001;32(6):862-870.
61. Diuk-Wasser MA, Vannier E, Krause PJ. Coinfection by Ixodes tick-borne pathogens: ecological, epidemiological, and clinical consequences. Trends Parasitol. 2016;32(1):30-42.
62. Herwaldt BL, Linden JV, Bosserman E, Young C, Olkowska D, Wilson M. Transfusion-associated babesiosis in the United States: a description of cases. Ann Intern Med. 2011;155(8):509-519.
63. Joseph JT, Purtill K, Wong SJ, et al. Vertical transmission of Babesia microti, United States. Emerg Infect Dis. 2012;18(8):1318-1321.
64. Cornett JK, Malhotra A, Hart D. Vertical transmission of babesiosis from a pregnant, splenectomized mother to her neonate. Infect Dis Clin Pract. 2012;20:408-410.
65. Bloch EM, Lee TH, Krause PJ, et al. Development of a real-time polymerase chain reaction assay for sensitive detection and quantitation of Babesia microti infection. Transfusion. 2013;53(10):2299-2306.
66. Rollend L, Bent SJ, Krause PJ, et al. Quantitative PCR for detection of Babesiamicroti in Ixodes scapularis ticks and in human blood. Vector Borne Zoonotic Dis. 2013;13(11):784-790.
67. Teal AE, Habura A, Ennis J, Keithly JS, Madison-Antenucci S. A new real-time PCR assay for improved detection of the parasite Babesia microti. J Clin Microbiol. 2012;50(3):903-908.
68. Wang G, Villafuerte P, Zhuge J, Visintainer P, Wormser GP. Comparison of a quantitative PCR assay with peripheral blood smear examination for detection and quantitation of Babesiamicroti infection in humans. Diagn Microbiol Infect Dis. 2015;82(2):109-113.
69. Wang G, Wormser GP, Zhuge J, et al. Utilization of a real-time PCR assay for diagnosis of Babesia microti infection in clinical practice. Ticks Tick Borne Dis. 2015;6(3):376-382.
70. Krause PJ, Spielman A, Telford SR III, et al. Persistent parasitemia after acute babesiosis. N Engl J Med. 1998;339(3):160-165.
71. Priest JW, Moss DM, Won K, et al. Multiplex assay detection of immunoglobulin G antibodies that recognize Babesiamicroti antigens. Clin Vaccine Immunol. 2012;19(9):1539-1548.
72. Levin AE, Williamson PC, Erwin JL, et al. Determination of Babesia microti seroprevalence in blood donor populations using an investigational enzyme immunoassay. Transfusion. 2014;54(9):2237-2244.
73. Persing DH, Herwaldt BL, Glaser C, et al. Infection with a babesia-like organism in northern California. N Engl J Med. 1995;332(5):298-303.
74. Hunfeld KP, Hildebrandt A, Gray JS. Babesiosis: recent insights into an ancient disease. Int J Parasitol. 2008;38(11):1219-1237.
75. Krause PJ, Telford SR III, Ryan R, et al. Diagnosis of babesiosis: evaluation of a serologic test for the detection of Babesiamicroti antibody. J Infect Dis. 1994;169(4):923-926.
76. Kowalski TJ, Tata S, Berth W, Mathiason MA, Agger WA. Antibiotic treatment duration and long-term outcomes of patients with early Lyme disease from a Lyme disease-hyperendemic area. Clin Infect Dis. 2010;50(4):512-520.
77. Wormser GP, Ramanathan R, Nowakowski J, et al. Duration of antibiotic therapy for early Lyme disease: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2003;138(9):697-704.
78. Ljostad U, Skogvoll E, Eikeland R, et al. Oral doxycycline versus intravenous ceftriaxone for European Lyme neuroborreliosis: a multicentre, non-inferiority, double-blind, randomised trial. Lancet Neurol. 2008;7(8):690-695.
79. Borg R, Dotevall L, Hagberg L, et al. Intravenous ceftriaxone compared with oral doxycycline for the treatment of Lyme neuroborreliosis. Scand J Infect Dis. 2005;37(6-7):449-454.
80. Dotevall L, Hagberg L. Successful oral doxycycline treatment of Lyme disease-associated facial palsy and meningitis. Clin Infect Dis. 1999;28(3):569-574.
81. Karlsson M, Hammers-Berggren S, Lindquist L, Stiernstedt G, Svenungsson B. Comparison of intravenous penicillin G and oral doxycycline for treatment of Lyme neuroborreliosis. Neurology. 1994;44(7):1203-1207.
82. Bremell D, Dotevall L. Oral doxycycline for Lyme neuroborreliosis with symptoms of encephalitis, myelitis, vasculitis, or intracranial hypertension. Eur J Neurol. 2014;21(9):1162-1167.
83. Luft BJ, Dattwyler RJ, Johnson RC, et al. Azithromycin compared with amoxicillin in the treatment of erythema migrans: a double-blind, randomized, controlled trial. Ann Intern Med. 1996;124(9):785-791.
84. Strle F, Maraspin V, Lotric-Furlan S, Ruzić-Sabljić E, Cimperman J. Azithromycin and doxycycline for treatment of Borrelia culture-positive erythema migrans. Infection. 1996;24(1):64-68.
85. Arnez M, Pleterski-Rigler D, Luznik-Bufon T, Ruzić-Sabljić E, Strle F. Solitary erythema migrans in children: comparison of treatment with azithromycin and phenoxymethylpenicillin. Wien KlinWochenschr. 2002;114(13-14):498-504.
86. Arnež M, Ružić-Sabljić E. Azithromycin is equally effective as amoxicillin in children with solitary erythema migrans. Pediatr Infect Dis J. 2015;34(10):1045-1048.
87. Nadelman RB, Luger SW, Frank E, Wisniewski M, Collins JJ, Wormser GP. Comparison of cefuroxime axetil and doxycycline in the treatment of early Lyme disease. Ann Intern Med. 1992;117(4):273-280.
88. Luger SW, Paparone P, Wormser GP, et al. Comparison of cefuroxime axetil and doxycycline in treatment of patients with early Lyme disease associated with erythema migrans. Antimicrob Agents Chemother. 1995;39(3):661-667.
89. Herwaldt BL, Springs FE, Roberts PP, et al. Babesiosis in Wisconsin: a potentially fatal disease. Am J Trop Med Hyg. 1995;53(2):146-151.
90. Wroblewski HA, Kovacs RJ, Kingery JR, Overholser BR, Tisdale JE. High risk of QT interval prolongation and torsades de pointes associated with intravenous quinidine used for treatment of resistant malaria or babesiosis. Antimicrob Agents Chemother. 2012;56(8):4495-4499.
91. Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM. Azithromycin and the risk of cardiovascular death. N Engl J Med. 2012;366(20):1881-1890.
92. Wittner M, Lederman J, Tanowitz HB, Rosenbaum GS, Weiss LM. Atovaquone in the treatment of Babesiamicroti infections in hamsters. Am J Trop Med Hyg. 1996;55(2):219-222.
93. Shatzel JJ, Donohoe K, Chu NQ, et al. Profound autoimmune hemolysis and Evans syndrome in two asplenic patients with babesiosis. Transfusion. 2015;55(3):661-665.
94. Weiss LM, Wittner M, Tanowitz HB. The treatment of babesiosis. N Engl J Med. 2001;344(10):773.
95. Hamburg BJ, Storch GA, Micek ST, Kollef MH. The importance of early treatment with doxycycline in human ehrlichiosis. Medicine (Baltimore). 2008;87(2):53-60.
96. Bakken JS, Dumler S. Human granulocytic anaplasmosis. Infect Dis Clin North Am. 2008;22(3):433-448.
97. Buitrago MI, Ijdo JW, Rinaudo P, et al. Human granulocytic ehrlichiosis during pregnancy treated successfully with rifampin. Clin Infect Dis. 1998;27(1):213-215.
98. Krause PJ, Corrow CL, Bakken JS. Successful treatment of human granulocytic ehrlichiosis in children using rifampin. Pediatrics. 2003;112(3, pt 1):e252-e253.
99. Krause PJ, Lepore T, Sikand VK, et al. Atovaquone and azithromycin for the treatment of babesiosis. N Engl JMed. 2000;343(20):1454-1458.
100. Krause PJ, Gewurz BE, Hill D, et al. Persistent and relapsing babesiosis in immunocompromised patients. Clin Infect Dis. 2008;46(3):370-376.
101. Wormser GP, Prasad A, Neuhaus E, et al. Emergence of resistance to azithromycinatovaquone in immunocompromised patients with Babesia microti infection. Clin Infect Dis. 2010;50(3):381-386.
102. Häselbarth K, Tenter AM, Brade V, Krieger G, Hunfeld KP. First case of human babesiosis in Germany-clinical presentation and molecular characterisation of the pathogen. Int J Med Microbiol. 2007;297(3):197-204.
103. Vyas JM, Telford SR, Robbins GK. Treatment of refractory Babesiamicroti infection with atovaquone-proguanil in an HIV-infected patient: case report. Clin Infect Dis. 2007;45(12):1588-1590.
104. Lubin AS, Snydman DR, Miller KB. Persistent babesiosis in a stem cell transplant recipient. Leuk Res. 2011;35(6):e77-e78.
105. Stowell CP, Gelfand JA, Shepard JA, Kratz A. Case records of the Massachusetts General Hospital: case 17-2007: a 25-year-old woman with relapsing fevers and recent onset of dyspnea. N Engl J Med. 2007;356(22):2313-2319.
106. Spaete J, Patrozou E, Rich JD, Sweeney JD. Red cell exchange transfusion for babesiosis in Rhode Island. J Clin Apher. 2009;24(3):97-105.
107. El Khoury MY, Gandhi R, Dandache P, Lombardo G, Wormser GP. Non-surgical management of spontaneous splenic rupture due to Babesiamicroti infection. Ticks Tick Borne Dis. 2011;2(4):235-238.
108. Farber FR, Muehlenbachs A, Robey TE. Atraumatic splenic rupture from Babesia: a disease of the otherwise healthy patient. Ticks Tick Borne Dis. 2015;6(5):649-652.
109. Wormser GP, Lombardo G, Silverblatt F, et al. Babesiosis as a cause of fever in patients undergoing a splenectomy. Am Surg. 2011;77(3):345-347.
110. Semel ME, Tavakkolizadeh A, Gates JD. Babesiosis in the immediate postoperative period after splenectomy for trauma. Surg Infect (Larchmt). 2009;10(6):553-556.
111. Krause PJ, Telford SR III, Spielman A, et al. Concurrent Lyme disease and babesiosis: evidence for increased severity and duration of illness. JAMA. 1996;275(21):1657-1660.
112. Krause PJ, McKay K, Thompson CA, et al; Deer-Associated Infection Study Group. Disease-specific diagnosis of coinfecting tickborne zoonoses: babesiosis, human granulocytic ehrlichiosis, and Lyme disease. Clin Infect Dis. 2002;34(9):1184-1191.
113. Horowitz HW, Aguero-Rosenfeld ME, Holmgren D, et al. Lyme disease and human granulocytic anaplasmosis coinfection: impact of case definition on coinfection rates and illness severity. Clin Infect Dis. 2013;56(1):93-99.
114. Belongia EA, Reed KD, Mitchell PD, et al. Clinical and epidemiological features of early Lyme disease and human granulocytic ehrlichiosis in Wisconsin. Clin Infect Dis. 1999;29(6):1472-1477.
115. Platonov AE, Karan LS, Kolyasnikova NM, et al. Humans infected with relapsing fever spirochete Borrelia miyamotoi, Russia. Emerg Infect Dis. 2011;17(10):1816-1823.
116. Gugliotta JL, Goethert HK, Berardi VP, Telford SR III. Meningoencephalitis from Borrelia miyamotoi in an immunocompromised patient. N Engl J Med. 2013;368(3):240-245.
117. Hovius JW, De Wever B, Sohne M, et al. A case of meningoencephalitis by the relapsing fever spirochaete Borrelia miyamotoi in Europe. Lancet. 2013;382(9892):658.
118. Chowdri HR, Gugliotta JL, Berardi VP, et al. Borrelia miyamotoi infection presenting as human granulocytic anaplasmosis: a case report. Ann Intern Med. 2013;159(1):21-27.
119. Molloy PJ, Telford SR III, Chowdri HR, et al. Borrelia miyamotoi disease in the Northeastern United States: a case series. Ann Intern Med. 2015;163(2):91-98.
120. Krause PJ, Narasimhan S, Wormser GP, et al. Human Borrelia miyamotoi infection in the United States. N Engl J Med. 2013;368(3):291-293.
121. Krause PJ, Narasimhan S, Wormser GP, et al; Tick Borne Diseases Group. Borrelia miyamotoi sensu lato seroreactivity and seroprevalence in the northeastern United States. Emerg Infect Dis. 2014;20(7):1183-1190.
122. Pritt BS, Mead PS, Johnson DK, et al. Identification of a novel pathogenic Borrelia species causing Lyme borreliosis with unusually high spirochaetaemia: a descriptive study [published online February 5, 2016]. Lancet Infect Dis. doi: 10.1016/S1473-3099 (15) 00464-8.
123. Hinten SR, Beckett GA, Gensheimer KF, et al. Increased recognition of Powassan encephalitis in the United States, 1999-2005. Vector Borne Zoonotic Dis. 2008;8(6):733-740.
124. El Khoury MY, Camargo JF, White JL, et al. Potential role of deer tick virus in Powassan encephalitis cases in Lyme disease-endemic areas of New York, U. S. A. Emerg Infect Dis. 2013;19(12):1926-1933.
125. Wormser GP, Pritt B. Update and commentary on four emerging tick-borne infections: Ehrlichia muris-like agent, Borrelia miyamotoi, deer tick virus, heartland virus, and whether ticks play a role in transmission of Bartonella henselae. Infect Dis Clin North Am. 2015;29(2):371-381.
126. Pritt BS, Sloan LM, Johnson DK, et al. Emergence of a new pathogenic Ehrlichia species, Wisconsin and Minnesota, 2009. N Engl J Med. 2011;365(5):422-429.
127. Nadelman RB, Nowakowski J, Fish D, et al; Tick Bite Study Group. Prophylaxis with single-dose doxycycline for the prevention of Lyme disease after an Ixodes scapularis tick bite. N Engl J Med. 2001;345(2):79-84.
128. Centers for Disease Control and Prevention (CDC). Preventing Tick Bites. CDC website. http://www.cdc.gov/ticks/avoid/on-people.html. 2015. Accessed March 22, 2016.
129. Connally NP, Durante AJ, Yousey-Hindes KM, Meek JI, Nelson RS, Heimer R. Peridomestic Lyme disease prevention: results of a population-based case-control study. Am J Prev Med. 2009;37(3):201-206.
130. Vázquez M, Muehlenbein C, Cartter M, Hayes EB, Ertel S, Shapiro ED. Effectiveness of personal protective measures to prevent Lyme disease. Emerg Infect Dis. 2008;14(2):210-216.
131. Carroll JF. A cautionary note: survival of nymphs of two species of ticks (Acari: Ixodidae) among clothes laundered in an automatic washer. J Med Entomol. 2003;40(5):732-736.
132. Hinckley AF, Meek JI, Ray JA, et al. Effectiveness of residential acaricides to prevent Lyme and other tick-borne diseases in humans [published online January 5, 2016]. J Infect Dis. 2016; jiv775. doi:10.1093/infdis/jiv775.
133. Grear JS, Koethe R, Hoskins B, Hillger R, Dapsis L, Pongsiri M. The effectiveness of permethrin-treated deer stations for control of the Lyme disease vector Ixodes scapularis on Cape Cod and the islands: a five-year experiment. Parasit Vectors. 2014;7:292.
134. Solberg VB, Miller JA, Hadfield T, Burge R, Schech JM, Pound JM. Control of Ixodes scapularis (Acari: Ixodidae) with topical self-application of permethrin by white-tailed deer inhabiting NASA, Beltsville, Maryland. J Vector Ecol. 2003;28(1):117-134.
135. Deblinger RD, Rimmer DW. Efficacy of a permethrin-based acaricide to reduce the abundance of Ixodes dammini (Acari: Ixodidae). J Med Entomol. 1991;28(5):708-711.
136. Stafford KC III. Effectiveness of host-targeted permethrin in the control of Ixodes dammini (Acari: Ixodidae). J Med Entomol. 1991;28(5):611-617.